New Centre to Deliver Real-Time, Personalised Immunotherapy for Cancer Patients
A new research centre at The Alfred hospital will use advanced imaging and cellular tools to monitor cancer patients' immune responses in real time, personalising their treatment.
Victorian cancer patients are set to benefit from a new, cutting-edge approach to immunotherapy, thanks to the launch of the Australian Cancer Research Foundation (ACRF) Centre for Dynamic Immuno-Oncology (CDIO) at The Alfred hospital.
The new centre is funded by a $2 million grant from the ACRF, alongside a $700,000 contribution from the National Imaging Facility.
A New Era of Personalised Treatment
The CDIO will allow doctors to move beyond standardised immunotherapy protocols by using advanced imaging and cellular-level immunology tools. This will enable them to track exactly how a patient's immune system is responding to treatment in real time.
This real-time monitoring is the key innovation, allowing clinicians to adapt therapies dynamically for each individual patient, rather than relying on a one-size-fits-all approach.
Leveraging World-Class Infrastructure
The CDIO will build on existing, world-class technology at The Alfred, including the state-of-the-art $24 million Quadra PET/CT scanner.
This powerful infrastructure, combined with the new centre's specialised immunology tools, will provide an unprecedented level of detail into how cancer cells and the immune system interact.
Location and Integration
The CDIO will be based at The Alfred’s Paula Fox Melanoma and Cancer Centre, integrating with the hospital's existing leading-edge cancer care and research programs.